By Dave Muoio
The daily-use digital intervention yielded “clinically meaningful” improvement in blood pressure among 172 users.
A study published last month in JMIR Cardio demonstrated significant systolic and diastolic blood pressure reductions in hypertension patients who received a mobile app-based behavior change intervention.
The investigation examined Better Therapeutics’ candidate digital therapeutic for cardiovascular disease, a daily-use app that encourages users to set and record their progress toward individualized behavioral goals. The app is supported by a remote multidisciplinary team that looks to support healthy behavior changes, with users receiving scheduled calls from a health coach over the course of a 12-week program.
The study was sponsored by Better Therapeutics and headed up by its employees.
Among 172 participants with hypertension, 75 percent achieved a “clinically meaningful” improvement in blood pressure. The group was 86 percent women and the mean age in the sample was 55.
Over an average of 62.6 days of app use, the mean change in systolic and diastolic blood pressure was –11.5 mmHg and –5.9 mmHg, respectively (P < .001). These reductions were even greater among those who completed the intervention (P = .02), as well as among patients whose conditions met the cutoff for stage 2 hypertension.
By 12 weeks, 43 percent of the participants who were still tracking their blood pressure had achieved control.
In addition, the researchers noted that a proof-of-concept machine learning model trained on 427 participants to predict whether or not they would complete the full treatment was generally successful, achieving a .78 area under the receiver operating characteristic curve.